High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells

BACKGROUND: Adoptive transfer of natural killer (NK) cells with augmented antibody-dependent cellular cytotoxicity (ADCC) capabilities and resistance to CD38 targeting has the potential to enhance the clinical anti-myeloma activity of daratumumab (DARA). Therefore, we sought to develop an efficient...

Descripción completa

Detalles Bibliográficos
Autores principales: Clara, Joseph Andrew, Levy, Emily R, Reger, Robert, Barisic, Stefan, Chen, Long, Cherkasova, Elena, Chakraborty, Mala, Allan, David S J, Childs, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830298/
https://www.ncbi.nlm.nih.gov/pubmed/35135865
http://dx.doi.org/10.1136/jitc-2021-003804

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8830298/
https://www.ncbi.nlm.nih.gov/pubmed/35135865
http://dx.doi.org/10.1136/jitc-2021-003804

Ejemplares similares